Patients Views & Analysis

Views & Analysis

Patients

New Evidation CEO to double down on patient data empowerment

pharmaphorum spoke with Leslie Oley Wilberforce, Evidation's new CEO, about the company's unique approach to real-world data and her future plans.

Patients

From trauma to healing: How therapy complements medication i...

Trauma therapy is more than just talk – it’s an evidence-backed process that helps patients reframe, process, and recover from life-altering events.

Patients

pharmaphorum podcast Episode 189a, Marc Buyse

On patient-centric treatment decisions and the value of quan...

Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.

Patients

HCP with stethoscope with plus sign on it

Innovation without access is just a headline: Closing the ga...

More than 4.5 billion people - over half the world’s population - lack full coverage of essential health services.

Patients

The unexpected starting line: Solving drug affordability at ...

In early 2025, the White House renewed its push to lower prescription drug prices, part of an executive order aimed at easing patients' financial burdens.

Patients

Phyllis Arthur, Dr Larry Buchson, Sherri Berger, and Dr Luciana Borio discuss vaccine skepticism at BIO 2025.

BIO 2025: Planning, not panic, as BIO weighs in on US vaccin...

At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.

New Evidation CEO to double down on patient data empowerment

From trauma to healing: How therapy complements medication i...

On patient-centric treatment decisions and the value of quan...

Innovation without access is just a headline: Closing the ga...

The unexpected starting line: Solving drug affordability at ...

BIO 2025: Planning, not panic, as BIO weighs in on US vaccin...

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks